Purchase Order 36C26326P0209

The Department of Veterans Affairs, Veterans Integrated Service Network 23 (VISN 23) awarded Edwards Lifesciences LLC a $34,000 firm fixed-price purchase order for transcatheter aortic valve replacement (TAVR) systems on January 16, 2026, with an ultimate completion date of January 20, 2026. The contract, which carries no set-aside designation, supports the VA's mission to provide specialized cardiac care to veterans in the Minneapolis service area. Edwards Lifesciences LLC, a subsidiary of Edwards Lifesciences Corporation and a self-certified small disadvantaged business, is a leading manufacturer of advanced cardiovascular medical devices, including transcatheter heart valves and related cardiac technologies essential for structural heart disease treatment.

This purchase order is part of Edwards Lifesciences LLC's extensive contractual relationship with the VA system, which includes over 200 prime contract awards since 2025 and two indefinite delivery contracts valued at $7.45 million combined. The company maintains a primary indefinite delivery vehicle with VISN 21 ($6.5 million, 2026–2030) for surgical implant consignment services and a secondary IDV with VISN 15 ($950,000, 2025–2030) for cardiovascular device provision. These contracts establish Edwards Lifesciences LLC as the principal framework supplier of specialized cardiac implants across multiple VA service networks, ensuring consistent availability of transcatheter heart valves and related technologies critical to the VA's surgical programs and veteran patient outcomes.